Grines C L, Browne K F, Marco J, Rothbaum D, Stone G W, O'Keefe J, Overlie P, Donohue B, Chelliah N, Timmis G C
William Beaumont Hospital, Royal Oak, MI 48073-6769.
N Engl J Med. 1993 Mar 11;328(10):673-9. doi: 10.1056/NEJM199303113281001.
The success of thrombolytic therapy for acute myocardial infarction is limited by bleeding complications, the impossibility of reperfusing all occluded coronary arteries, recurrent myocardial ischemia, and the relatively small number of patients who are appropriate candidates for this therapy. We hypothesized that these problems could be overcome by the use of immediate percutaneous transluminal coronary angioplasty (PTCA), without previous thrombolytic therapy.
At 12 clinical centers, 395 patients who presented within 12 hours of the onset of myocardial infarction were treated with intravenous heparin and aspirin and then randomly assigned to undergo immediate PTCA (without previous thrombolytic therapy, 195 patients) or to receive intravenous tissue plasminogen activator (t-PA, 200 patients) followed by conservative care. Radionuclide ventriculography was performed to assess ventricular function within 24 hours and at six weeks.
Among the patients randomly assigned to PTCA, 90 percent underwent the procedure; the success rate was 97 percent, and no patient required emergency coronary-artery bypass surgery. The in-hospital mortality rates in the t-PA and PTCA groups were 6.5 and 2.6 percent, respectively (P = 0.06). In a post hoc analysis, the mortality rates in the subgroups classified as "not low risk" were 10.4 and 2.0 percent, respectively (P = 0.01). Reinfarction or death in the hospital occurred in 12.0 percent of the patients treated with t-PA and 5.1 percent of those treated with PTCA (P = 0.02). Intracranial bleeding occurred more frequently among patients who received t-PA than among those who underwent PTCA (2.0 vs. 0 percent, P = 0.05). The mean (+/- SD) ejection fractions at rest (53 +/- 13 vs. 53 +/- 13 percent) and during exercise (56 +/- 13 vs. 56 +/- 14 percent) were similar in the t-PA and PTCA groups at six weeks. By six months, reinfarction or death had occurred in 32 patients who received t-PA (16.8 percent) and 16 treated with PTCA (8.5 percent, P = 0.02).
As compared with t-PA therapy for acute myocardial infarction, immediate PTCA reduced the combined occurrence of nonfatal reinfarction or death, was associated with a lower rate of intracranial hemorrhage, and resulted in similar left ventricular systolic function.
急性心肌梗死溶栓治疗的成功受到出血并发症、无法使所有闭塞冠状动脉再灌注、复发性心肌缺血以及适合该治疗的患者数量相对较少的限制。我们假设通过直接经皮腔内冠状动脉成形术(PTCA),无需先前的溶栓治疗,可以克服这些问题。
在12个临床中心,对395例在心肌梗死发作12小时内就诊的患者给予静脉肝素和阿司匹林治疗,然后随机分为接受直接PTCA(无先前溶栓治疗,195例患者)或接受静脉注射组织型纤溶酶原激活剂(t-PA,200例患者)并随后进行保守治疗。在24小时内及六周时进行放射性核素心室造影以评估心室功能。
在随机分配接受PTCA的患者中,90%接受了该手术;成功率为97%,且无患者需要急诊冠状动脉搭桥手术。t-PA组和PTCA组的院内死亡率分别为6.5%和2.6%(P = 0.06)。在事后分析中,分类为“非低风险”亚组的死亡率分别为10.4%和2.0%(P = 0.01)。接受t-PA治疗的患者中有12.0%在医院发生再梗死或死亡,接受PTCA治疗的患者中有5.1%发生(P = 0.02)。接受t-PA的患者颅内出血发生率高于接受PTCA的患者(2.0%对0%,P = 0.05)。六周时,t-PA组和PTCA组静息时(53±13%对53±13%)及运动时(56±13%对56±14%)的平均(±标准差)射血分数相似。到六个月时,接受t-PA治疗的32例患者(16.8%)和接受PTCA治疗的16例患者(8.5%)发生了再梗死或死亡(P = 0.02)。
与急性心肌梗死的t-PA治疗相比,直接PTCA降低了非致命性再梗死或死亡的联合发生率,与较低的颅内出血率相关,并且导致相似的左心室收缩功能。